MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.crohns.2012.03.006

Медицинская библиотека · Journal of Crohn's & colitis · 2012

Long-term outcome of tumor necrosis factor alpha antagonist's treatment in pediatric Crohn's disease.

Assa Amit, Hartman Corina, Weiss Batia, Broide Efrat, Rosenbach Yoram, Zevit Noam, Bujanover Yoram, Shamir Raanan

СтатьяМногоцентровое исследованиеПеревод пока не подготовлен

Аннотация

BACKGROUND

Anti tumor necrosis factor alpha (TNFα) agents have become widely used in pediatric inflammatory bowel disease (IBD). So far, only few studies examined the long-term results of anti-TNFα treatment in children with IBD.

METHODS

The long-term outcome of pediatric patients with IBD was assessed retrospectively in a multicenter cohort of children treated with anti-TNFα beyond induction treatment. Short- and long-term response rates, predictors for loss of response, data on growth and laboratory parameters were assessed.

RESULTS

120 patients [101 crohn's disease (CD), 19 ulcerative colitis (UC) or indeterminate colitis (IC)] received either infliximab or adalimumab. The mean age at initiation of anti-TNFα was 13.4 ± 3.9 years and the median duration of anti-TNFα treatment was 15 months (range: 2-90). Overall, 89% of the cohort experienced short-term response following induction. Response was associated with improvement in weight and BMI Z-scores (p<0.001) but not with linear growth. Responders experienced a significant decrease in erythrocyte sedimentation rate (ESR) and C reactive protein (CRP) during treatment (p<0.001). Albumin and hemoglobin both improved but only albumin increased significantly (p<0.001). The cumulative probability of losing response to anti-TNFα treatment was 17%, 38%, and 49% after 1, 3, and 5 years, respectively. Responders had a significantly lower weight and BMI Z-scores at initiation of anti-TNFα treatment in compared to non-responders (p=0.04 and 0.02 respectively).

CONCLUSIONS

Our long term cohort supports the current evidence on the effectiveness and safety of anti-TNFα treatment in children with IBD. Response to treatment was interestingly associated with lower weight and BMI.

Для цитирования: Assa Amit, Hartman Corina, Weiss Batia, Broide Efrat, Rosenbach Yoram, Zevit Noam, Bujanover Yoram, Shamir Raanan. Long-term outcome of tumor necrosis factor alpha antagonist's treatment in pediatric Crohn's disease.. Journal of Crohn's & colitis. 2012. DOI: 10.1016/j.crohns.2012.03.006.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.